English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, June 9, 2021
エーザイ、第3回「プラチナキャリア・アワード」において特別賞を受賞
Eisai Receives Special Prize at Platinum Career Award 2021
エーザイ、レンボレキサントの最新データを第35回米国睡眠学会年次総会において発表
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
Tuesday, June 8, 2021
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
バイオジェンとエーザイ、ADUHELM(TM)についてアルツハイマー病の病理に作用する初めてかつ唯一の治療薬として米国FDAより迅速承認を取得
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
Wednesday, June 2, 2021
エーザイ、人事異動(2021年6月1日付)を発表
Monday, May 31, 2021
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575